48/120
2.0 / 5 stars
All 120 Win/Lose results shown below
MNKD Roast Me summary
MANNKIND CORP (MNKD). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Win.
Trailing 1 year (4 quarters): 8 wins, 4 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinMNKD / S&P 73.88% / 15.20% |
WinMNKD / S&P 30.46% / 15.00% |
LoseMNKD / S&P -218.18% / 50.40% |
| 2026-Q11/3 |
LoseMNKD / S&P -56.79% / -4.33% |
WinMNKD / S&P 21.23% / 11.30% |
LoseMNKD / S&P -170.00% / 27.70% |
| 2025-Q42/3 |
WinMNKD / S&P 5.59% / 2.65% |
WinMNKD / S&P 22.23% / 9.00% |
LoseMNKD / S&P -80.00% / 13.40% |
| 2025-Q33/3 |
WinMNKD / S&P 43.58% / 8.12% |
WinMNKD / S&P 17.44% / 4.61% |
WinMNKD / S&P 25.00% / 13.45% |
| 2025-Q22/3 |
LoseMNKD / S&P -25.65% / 10.94% |
WinMNKD / S&P 21.48% / 4.83% |
WinMNKD / S&P 120.00% / 10.63% |
| 2025-Q12/3 |
LoseMNKD / S&P -21.77% / -4.27% |
WinMNKD / S&P 32.50% / 4.98% |
WinMNKD / S&P 150.00% / 10.57% |
| 2024-Q41/3 |
LoseMNKD / S&P 2.23% / 2.41% |
WinMNKD / S&P 43.50% / 5.25% |
LoseMNKD / S&P MNKD unavailable / 6.15% |
| 2024-Q32/3 |
WinMNKD / S&P 20.50% / 5.89% |
WinMNKD / S&P 51.35% / 5.89% |
LoseMNKD / S&P MNKD unavailable / 6.11% |
| 2024-Q22/3 |
WinMNKD / S&P 15.23% / 4.28% |
WinMNKD / S&P 57.08% / 5.38% |
LoseMNKD / S&P MNKD unavailable / 5.12% |
| 2024-Q12/3 |
WinMNKD / S&P 24.45% / 10.56% |
WinMNKD / S&P 74.92% / 5.71% |
LoseMNKD / S&P MNKD unavailable / 5.59% |
| 2023-Q41/3 |
LoseMNKD / S&P -11.86% / 11.69% |
WinMNKD / S&P 99.42% / 6.81% |
LoseMNKD / S&P MNKD unavailable / 7.78% |
| 2023-Q32/3 |
WinMNKD / S&P 1.47% / -3.27% |
WinMNKD / S&P 131.61% / 7.52% |
LoseMNKD / S&P MNKD unavailable / -5.03% |
| 2023-Q21/3 |
LoseMNKD / S&P -0.73% / 8.74% |
WinMNKD / S&P 140.99% / 9.50% |
LoseMNKD / S&P MNKD unavailable / -8.57% |
| 2023-Q11/3 |
LoseMNKD / S&P -22.20% / 7.50% |
WinMNKD / S&P 83.44% / 10.77% |
LoseMNKD / S&P MNKD unavailable / -15.69% |
| 2022-Q42/3 |
WinMNKD / S&P 70.55% / 7.56% |
WinMNKD / S&P 32.25% / 11.88% |
LoseMNKD / S&P MNKD unavailable / -17.99% |
| 2022-Q30/3 |
LoseMNKD / S&P -18.90% / -4.88% |
LoseMNKD / S&P -6.32% / 13.47% |
LoseMNKD / S&P MNKD unavailable / -1.41% |
| 2022-Q21/3 |
WinMNKD / S&P 3.53% / -16.10% |
LoseMNKD / S&P -11.94% / 13.71% |
LoseMNKD / S&P MNKD unavailable / 11.04% |
| 2022-Q10/3 |
LoseMNKD / S&P -15.79% / -4.60% |
LoseMNKD / S&P 5.51% / 15.97% |
LoseMNKD / S&P MNKD unavailable / 42.23% |
| 2021-Q41/3 |
LoseMNKD / S&P 0.46% / 11.03% |
WinMNKD / S&P 15.81% / 15.00% |
LoseMNKD / S&P MNKD unavailable / 96.40% |
| 2021-Q31/3 |
LoseMNKD / S&P -20.18% / 0.58% |
WinMNKD / S&P 29.79% / 10.77% |
LoseMNKD / S&P MNKD unavailable / 69.42% |
| 2021-Q22/3 |
WinMNKD / S&P 39.03% / 8.55% |
WinMNKD / S&P 20.30% / 6.58% |
LoseMNKD / S&P MNKD unavailable / 51.81% |
| 2021-Q12/3 |
WinMNKD / S&P 25.24% / 6.17% |
WinMNKD / S&P 7.31% / -1.06% |
LoseMNKD / S&P MNKD unavailable / 7.39% |
| 2020-Q42/3 |
WinMNKD / S&P 66.49% / 12.15% |
WinMNKD / S&P 3.34% / -3.72% |
LoseMNKD / S&P MNKD unavailable / -33.42% |
| 2020-Q31/3 |
LoseMNKD / S&P 7.43% / 8.93% |
WinMNKD / S&P -0.61% / -2.04% |
LoseMNKD / S&P MNKD unavailable / -27.10% |
| 2020-Q22/3 |
WinMNKD / S&P 69.90% / 20.54% |
WinMNKD / S&P 16.97% / -0.46% |
LoseMNKD / S&P MNKD unavailable / -27.11% |
| 2020-Q11/3 |
LoseMNKD / S&P -20.16% / -19.60% |
WinMNKD / S&P 47.76% / 3.47% |
LoseMNKD / S&P MNKD unavailable / -14.75% |
| 2019-Q41/3 |
LoseMNKD / S&P 3.20% / 9.07% |
WinMNKD / S&P 126.28% / 5.36% |
LoseMNKD / S&P MNKD unavailable / 2.99% |
| 2019-Q32/3 |
WinMNKD / S&P 8.70% / 1.70% |
WinMNKD / S&P 285.63% / 5.02% |
LoseMNKD / S&P MNKD unavailable / 0.21% |
| 2019-Q21/3 |
LoseMNKD / S&P -41.62% / 4.30% |
WinMNKD / S&P 280.09% / 6.64% |
LoseMNKD / S&P MNKD unavailable / 8.65% |
| 2019-Q12/3 |
WinMNKD / S&P 85.85% / 13.65% |
WinMNKD / S&P 242.94% / 8.12% |
LoseMNKD / S&P MNKD unavailable / 14.29% |
| 2018-Q41/3 |
LoseMNKD / S&P -42.08% / -13.52% |
WinMNKD / S&P 137.20% / 9.05% |
LoseMNKD / S&P MNKD unavailable / 18.23% |
| 2018-Q30/3 |
LoseMNKD / S&P -3.68% / 7.71% |
LoseMNKD / S&P -16.63% / 10.21% |
LoseMNKD / S&P MNKD unavailable / 19.06% |
| 2018-Q20/3 |
LoseMNKD / S&P -16.67% / 3.43% |
LoseMNKD / S&P -92.26% / 9.03% |
LoseMNKD / S&P MNKD unavailable / 14.46% |
| 2018-Q10/3 |
LoseMNKD / S&P -1.72% / -0.76% |
LoseMNKD / S&P -93.14% / 7.68% |
LoseMNKD / S&P MNKD unavailable / 12.46% |
| 2017-Q41/3 |
WinMNKD / S&P 6.91% / 6.64% |
LoseMNKD / S&P -93.28% / 7.03% |
LoseMNKD / S&P -183.09% / 13.82% |
| 2017-Q31/3 |
WinMNKD / S&P 53.90% / 4.48% |
LoseMNKD / S&P -87.92% / 5.68% |
LoseMNKD / S&P MNKD unavailable / 17.57% |
| 2017-Q20/3 |
LoseMNKD / S&P -4.73% / 3.09% |
LoseMNKD / S&P MNKD unavailable / 4.83% |
LoseMNKD / S&P MNKD unavailable / 17.74% |
| 2017-Q10/3 |
LoseMNKD / S&P -53.75% / 6.07% |
LoseMNKD / S&P MNKD unavailable / 3.67% |
LoseMNKD / S&P MNKD unavailable / 13.32% |
| 2016-Q40/3 |
LoseMNKD / S&P 3.23% / 3.82% |
LoseMNKD / S&P MNKD unavailable / 2.09% |
LoseMNKD / S&P MNKD unavailable / 7.05% |
| 2016-Q30/3 |
LoseMNKD / S&P -46.55% / 3.85% |
LoseMNKD / S&P MNKD unavailable / 0.20% |
LoseMNKD / S&P MNKD unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | MNKD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -13.94% | 20.78% |
| Annualized return | -13.94% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | MNKD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -17.71% | 83.14% |
| Annualized return | -3.82% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | MNKD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 6.76% | 319.30% |
| Annualized return | 0.66% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |